Related Experiment Video
Updated: Jul 27, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Drug-eluting stents in vascular intervention
Rossella Fattori1, Tommaso Piva
1Department of Radiology, Cardiovascular Unit, University Hospital S Orsola, 40138, Bologna, Italy. ross@med.unibo.it
Lancet (London, England)
|January 28, 2003
Summary
Drug-eluting stents, like those coated with sirolimus, effectively prevent restenosis after coronary procedures. This local drug delivery approach offers a promising solution to in-stent restenosis, improving patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomedical Engineering
Background:
- Restenosis, or in-stent restenosis, is a significant complication following coronary stent implantation, driven by neointimal hyperplasia.
- Current treatments for restenosis have limited success, posing clinical and economic challenges.
- Local drug delivery via coated stents offers a targeted approach to inhibit neointimal proliferation.
Purpose of the Study:
- To evaluate the efficacy of sirolimus-coated stents in preventing restenosis after percutaneous coronary interventions.
- To assess the long-term safety and effectiveness of local sirolimus delivery.
Main Methods:
- Utilized multicenter trials involving patients undergoing percutaneous coronary interventions with either sirolimus-coated stents or conventional stents.
- Followed patients for up to 6 months and 2 years to assess restenosis rates and adverse events.
Main Results:
- Sirolimus-coated stents demonstrated a significant reduction in restenosis, with 0% restenosis observed at 6 months compared to 27% in the control group (p<0.001).
- Two-year follow-up confirmed persistent inhibition of restenosis and no unexpected adverse events.
Conclusions:
- Local drug delivery using sirolimus-coated stents is a highly effective strategy for preventing in-stent restenosis.
- This approach holds significant promise for improving the management of coronary artery disease and reducing healthcare costs.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...